{"article_title": "As Pricey Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles", "article_keywords": ["hurdles", "hepatitis", "states", "sovaldi", "pricey", "medicaid", "erect", "joins", "harvoni", "pill"], "article_url": "http://www.forbes.com/sites/brucejapsen/2014/10/10/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "Bruce Japsen", "og": {"site_name": "Forbes", "description": "As Gilead Sciences (GILD) launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage restrictions. Already, the cost of Gilead\u2019s first generation Hepatitis C drug Sovaldi, which costs $1,000 a pill and more than $84,000 for [...]", "title": "As Pricey Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles", "url": "http://www.forbes.com/sites/brucejapsen/2014/10/10/as-hepatitis-pill-harvoni-joins-sovaldi-states-erect-medicaid-hurdles/", "image": "http://blogs-images.forbes.com/brucejapsen/files/2014/10/Sovaldi--1940x1298.jpg", "updated_time": "2014-10-10T15:31:34-04:00", "type": "article"}, "twitter": {"description": "As Gilead Sciences (GILD) launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage restrictions. Already, the cost of Gilead\u2019s first generation Hepatitis C drug Sovaldi, which costs $1,000 a pill and more than $84,000 for [...]", "creator": "@brucejapsen", "image": "http://blogs-images.forbes.com/brucejapsen/files/2014/10/Sovaldi--1940x1298.jpg", "title": "As Pricey Hepatitis Pill Harvoni Joins Sovaldi, States Erect Medicaid Hurdles", "site": "@forbes", "card": "summary_large_image"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Business,Health,Healthcare Innovation,Lifestyle,Pharma and Health,Retail,Wall Street,Washington,Pharma &amp; Healthcare,The Economy", "article": {"publisher": "https://www.facebook.com/forbes", "section_url": "http://www.forbes.com/business", "section": "Business", "modified": "2014-10-10", "published": "2014-10-10", "id": "blogAndPostId/blog/post/2125-8299"}, "news_keywords": "Business,Health,Healthcare Innovation,Lifestyle,Pharma and Health,Retail,Wall Street,Washington,Pharma &amp; Healthcare,The Economy", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "description": "As Gilead Sciences (GILD) launches its next generation Hepatitis C pill, Harvoni, Medicaid programs are bracing for another extraordinary wave of costs, with 70 percent of states implementing coverage restrictions. Already, the cost of Gilead\u2019s first generation Hepatitis C drug Sovaldi, which costs $1,000 a pill and more than $84,000 for [...]"}, "_id": "\"57477af46914bd0286fdc48c\"", "article_summary": ""}